Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Crosses Above 200-Day Moving Average – Should You Sell?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $47.58 and traded as high as $51.41. Supernus Pharmaceuticals shares last traded at $50.84, with a volume of 738,653 shares.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on SUPN shares. Bank of America assumed coverage on shares of Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They set a “buy” rating and a $65.00 price target for the company. TD Cowen boosted their price objective on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, October 23rd. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Wall Street Zen lowered Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 31st. Finally, Stifel Nicolaus increased their price objective on Supernus Pharmaceuticals from $50.00 to $55.00 and gave the company a “hold” rating in a research note on Friday, December 19th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Supernus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $61.60.

Supernus Pharmaceuticals Stock Up 2.0%

The firm has a market capitalization of $2.92 billion, a PE ratio of -149.53, a price-to-earnings-growth ratio of 0.64 and a beta of 0.71. The business has a 50-day moving average price of $49.80 and a 200-day moving average price of $47.58.

Insider Buying and Selling at Supernus Pharmaceuticals

In related news, SVP Frank Mottola sold 20,000 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the completion of the sale, the senior vice president directly owned 15,496 shares in the company, valued at approximately $781,153.36. This trade represents a 56.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Padmanabh P. Bhatt sold 710 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of $44.44, for a total transaction of $31,552.40. Following the transaction, the vice president directly owned 14,508 shares in the company, valued at $644,735.52. This trade represents a 4.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Hantz Financial Services Inc. raised its position in shares of Supernus Pharmaceuticals by 81.7% during the 3rd quarter. Hantz Financial Services Inc. now owns 625 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 281 shares during the period. Torren Management LLC purchased a new position in Supernus Pharmaceuticals in the fourth quarter worth approximately $49,000. USA Financial Formulas acquired a new stake in Supernus Pharmaceuticals during the third quarter worth $50,000. EverSource Wealth Advisors LLC acquired a new stake in Supernus Pharmaceuticals during the second quarter worth $51,000. Finally, Smartleaf Asset Management LLC raised its position in Supernus Pharmaceuticals by 30.8% in the third quarter. Smartleaf Asset Management LLC now owns 1,137 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 268 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.